New drug combo aims to silence hepatitis b virus

NCT ID NCT07709520

Recruiting now Disease control Sponsor: Fujian Akeylink Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase II trial tests whether two experimental drugs, GST-HG131 and GST-HG141, can safely reduce hepatitis B surface antigen (HBsAg) levels in people with chronic hepatitis B. The study involves 80 adults aged 35-65. Participants receive either the drug combination or a placebo, and researchers measure HBsAg decline after 168 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: two experimental drugs called GST-HG131 and GST-HG141
What this could lead to: If successful, this combination could point toward a new way to control chronic hepatitis B and reduce the risk of liver damage.
What could go wrong: This is an early phase II trial with only 80 participants, so results may not apply broadly. The drugs may not lower HBsAg enough or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.